Orgovyx

Treatment of Advanced Prostate Cancer

Orgovyx is primarily used to treat advanced prostate cancer in adult patients. Prostate cancer often relies on male hormones, such as testosterone, to grow and spread. This medication belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) receptor antagonists.

The medication works by blocking the pituitary gland from signaling the testicles to produce testosterone. By lowering testosterone levels in the body, Orgovyx helps to:

• Slow the growth of prostate cancer cells.
• Shrink existing tumors or prevent them from getting larger.
• Manage the progression of the disease in its advanced stages.

Orgovyx is an oral treatment option, which may be prescribed as an alternative to injectable hormone therapies for patients with advanced prostate cancer.

Mechanism of Action

Orgovyx belongs to a class of medications known as gonadotropin-releasing hormone (GnRH) receptor antagonists. It is used to treat advanced prostate cancer by targeting the hormones that fuel cancer growth.

The medication works through the following process:

• Blocking Receptors: Orgovyx binds to and blocks GnRH receptors in the pituitary gland, a small gland at the base of the brain.
• Reducing Hormone Signals: By blocking these receptors, the drug prevents the release of two other hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
• Lowering Testosterone: Without LH and FSH, the testicles are not signaled to produce testosterone. This leads to a significant drop in testosterone levels in the blood.

Because many prostate cancer cells rely on testosterone to grow and spread, lowering the levels of this hormone can help shrink the tumor or slow the progression of the disease.

Common Side Effects

The most frequently reported side effects of Orgovyx include:

• Hot flashes
• Pain in the muscles, joints, or bones
• Fatigue or extreme tiredness
• Diarrhea
• Constipation
• Weight gain
• Decreased sexual desire or ability

Serious Side Effects

Some side effects can be severe and require immediate medical attention. These include:

• Heart rhythm problems: Orgovyx can cause changes in the heart's electrical activity. Symptoms may include feeling dizzy, lightheaded, or fainting.
• Heart attack and stroke: Seek emergency care for chest pain, shortness of breath, sudden numbness or weakness, or trouble speaking.
• Liver problems: Contact your doctor if you notice yellowing of the skin or eyes, dark urine, or pain in the upper right side of the stomach.
• Allergic reactions: Signs include a severe rash, hives, or swelling of the face, lips, or tongue.

Changes in Lab Tests

Orgovyx can affect certain blood test results. Your doctor may monitor you for increased blood sugar, higher levels of fats in the blood (triglycerides), decreased red blood cell counts (anemia), or changes in liver enzyme levels.

Heart Rhythm Changes

Orgovyx can cause a condition called QT prolongation, which affects the electrical activity of the heart. This change can increase the risk of developing serious or life-threatening heart rhythm problems. Healthcare providers may monitor heart health using an electrocardiogram (ECG) and perform blood tests to check electrolyte levels, such as potassium and magnesium, especially in individuals with a history of heart disease or those taking other medications that affect heart rhythm.

Embryo-Fetal Toxicity

Based on its mechanism of action, Orgovyx can cause harm to a developing fetus. Although it is used in males with prostate cancer, the following precautions are recommended for reproductive safety:

• Males with female partners of reproductive potential should use effective contraception during treatment.
• Effective birth control should be continued for at least 2 weeks after the final dose of Orgovyx.

Laboratory Monitoring

Regular monitoring is required to ensure the medication is working effectively. Healthcare providers typically use blood tests to measure Prostate-Specific Antigen (PSA) levels. An increase in PSA levels during treatment may indicate that the cancer is no longer responding to the medication.

Drug Interactions

Certain medications can change the levels of Orgovyx in the blood, which may increase the risk of side effects or make the drug less effective. It is important for healthcare providers to review all current medications, including over-the-counter drugs and herbal supplements, to manage potential interactions.

Pregnancy Considerations

Orgovyx is not approved for use in women. Based on findings from animal studies and the way the medication works, it can cause fetal harm or the loss of a pregnancy if a pregnant woman is exposed to it.

Men who have female partners of reproductive potential should use effective contraception during treatment with Orgovyx and for 2 weeks after the final dose to prevent pregnancy.

Breastfeeding

It is not known whether Orgovyx passes into human breast milk. Because of the potential for serious adverse reactions in a breastfed child, breastfeeding is not recommended during treatment and for 2 weeks after the last dose.

Fertility

Based on animal studies and the drug's effect on hormone levels, Orgovyx may impair male fertility. It is not currently known if these effects on fertility are reversible. Individuals concerned about fertility should discuss these risks with a healthcare provider.

Available Forms

Orgovyx is available in the following form for oral administration:

• Film-coated tablet

This medication is intended to be swallowed whole and should not be crushed or chewed.

FDA Approval History

The U.S. Food and Drug Administration (FDA) approved Orgovyx on December 18, 2020. It was the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved for the treatment of advanced prostate cancer. Before this approval, medications in this class were typically administered as injections or implants.

Approved Indications

Orgovyx is indicated for the treatment of adult patients with advanced prostate cancer. It works by blocking the GnRH receptor, which reduces the production of testosterone in the body. Because prostate cancer cells often rely on testosterone to grow, lowering these levels can help slow the progression of the disease.

Regulatory Safety Information

There are no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with Orgovyx. However, the FDA-approved labeling includes important safety considerations:

• QT Interval Prolongation: The medication can affect the electrical activity of the heart. Healthcare providers may monitor heart rhythm and electrolyte levels, especially in patients with pre-existing heart conditions.
• Embryo-Fetal Toxicity: Based on how the drug works, it can cause harm to a developing fetus. The FDA recommends that male patients with pregnant partners or partners who could become pregnant use effective contraception during treatment and for two weeks after the last dose.
• Hypersensitivity: Patients with a known severe hypersensitivity to relugolix or any of its components should not use this medication.

Factors Affecting Cost

Several factors can influence the out-of-pocket cost for Orgovyx:

• Insurance Coverage: Most Medicare Part D and private insurance plans provide coverage for Orgovyx, but the specific copay or coinsurance amount depends on your plan's formulary and benefit tier.
• Pharmacy Selection: Because Orgovyx is a specialty medication, it may be dispensed through specific specialty pharmacies, which can affect pricing and delivery options.
• Generic Availability: Currently, there is no generic version of relugolix available. Brand-name medications typically cost more than generic alternatives.

Financial Assistance and Support

Patients may be able to reduce their costs through various programs:

• Copay Savings Cards: The manufacturer may offer savings cards for patients with commercial insurance to help lower monthly out-of-pocket expenses.
• Patient Assistance Programs: Programs may be available for individuals who are uninsured or underinsured and meet specific financial criteria.
• Support Services: Specialized programs can help patients and healthcare providers navigate the insurance authorization process and identify potential sources of funding.

It is recommended to contact your insurance provider or pharmacist to determine the exact cost based on your specific coverage.